Florence Wong, Wesley Leung, Mohammed Al Beshir, Max Marquez, Eberhard L. Renner – 25 November 2014 – Hepatorenal syndrome type 1 (HRS1) is acute renal failure in the setting of advanced cirrhosis, and it results from hemodynamic derangements, which should be fully reversible after liver transplantation. However, the rate of hepatorenal syndrome (HRS) reversal and factors predicting renal outcomes after transplantation have not been fully elucidated. The aim of this study was to assess outcomes of HRS1 patients after liver transplantation and factors predicting HRS reversal.

James O'Beirne – 25 November 2014

Elisabeth Krones, Wolfgang Erwa, Michael Trauner, Peter Fickert – 25 November 2014

Julia Szendroedi, Michael Roden – 25 November 2014

Cristiano Quintini, Mario Spaggiari, Koji Hashimoto, Federico Aucejo, Teresa Diago, Masato Fujiki, Charles Winans, Giuseppe D'Amico, Loris Trenti, Dympna Kelly, Bijan Eghtesad, Charles Miller – 25 November 2014 – The presence of portal vein thrombosis (PVT) is still considered by many transplantation centers to be an absolute contraindication to liver transplantation because of the technical difficulties that it can present and its association with a higher rate of patient morbidity and mortality. Renoportal bypass (RPB) can help to remove these barriers.

Isaac Ruiz, Cyrille Feray, Jean‐Michel Pawlotsky, Christophe Hézode – 25 November 2014

Naoya Yamada, Yukihiro Sanada, Yuta Hirata, Noriki Okada, Taiichi Wakiya, Yoshiyuki Ihara, Atsushi Miki, Yuji Kaneda, Hideki Sasanuma, Taizen Urahashi, Yasunaru Sakuma, Yoshikazu Yasuda, Koichi Mizuta – 25 November 2014 – In the field of pediatric living donor liver transplantation (LDLT), physicians sometimes must reduce the volume of left lateral segment (LLS) grafts to prevent large‐for‐size syndrome. There are 2 established methods for decreasing the size of an LLS graft: the use of a segment 2 (S2) monosegment graft and the use of a reduced LLS graft.

Yuka Inaba, Tomoko Furutani, Kumi Kimura, Hitoshi Watanabe, Sanae Haga, Yoshiaki Kido, Michihiro Matsumoto, Yasuhiko Yamamoto, Kenichi Harada, Shuichi Kaneko, Seiichi Oyadomari, Michitaka Ozaki, Masato Kasuga, Hiroshi Inoue – 25 November 2014 – The liver has robust regenerative potential in response to damage, but hepatic steatosis (HS) weakens this potential.

Wendy L. van der Woerd, Johanna Mulder, Franco Pagani, Ulrich Beuers, Roderick H.J. Houwen, Stan F.J. van de Graaf – 25 November 2014 – ATP8B1 deficiency is a severe autosomal recessive liver disease resulting from mutations in the ATP8B1 gene characterized by a continuous phenotypical spectrum from intermittent (benign recurrent intrahepatic cholestasis; BRIC) to progressive familial intrahepatic cholestasis (PFIC). Current therapeutic options are insufficient, and elucidating the molecular consequences of mutations could lead to personalized mutation‐specific therapies.

Dustin R. Berger, Brenton R. Ware, Matthew D. Davidson, Samuel R. Allsup, Salman R. Khetani – 25 November 2014 – Induced pluripotent stem cell‐derived human hepatocyte‐like cells (iHeps) could provide a powerful tool for studying the mechanisms underlying human liver development and disease, testing the efficacy and safety of pharmaceuticals across different patients (i.e., personalized medicine), and enabling cell‐based therapies in the clinic.